News Focus
News Focus
Post# of 257262
Next 10
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

Re: jq1234 post# 167702

Wednesday, 10/09/2013 1:56:45 PM

Wednesday, October 09, 2013 1:56:45 PM

Post# of 257262
PTLA starts phase-1/2 trial of JAK inhibitor for “genetically-defined hematologic cancers”:

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-initiation-phase-120000609.html

This program is very far town on the valuation totem pole, below Betrixaban and PRT4445.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today